When using a control that doesn't block ER-α, there was no change in cancer cell growth, invasion, or death compared to normal cells.

Scientific Claim

ER-α knockdown in Hep3B and HCCLM3 human hepatocellular carcinoma cell lines did not significantly affect cell proliferation, invasion, or apoptosis when using nonsilencing siRNA or lentivirus alone as controls.

Original Statement

“whereas no significant inhibitory effect was observed in cells treated with NS siRNA, LV, or untreated cells (Figure 2(a)). NS siRNA group showed no significant differences in cell invasion compared with the control group (210 ± 34 versus 201 ± 36, P = 0.22) and LV group (210 ± 34 versus 214 ± 45, P = 0.034). Compared with the control group and LV group, NS siRNA did not significantly increase cell apoptosis (P > 0.05, resp.).”

From study:Unknown Title

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

definitive

Can make definitive causal claims

Assessment Explanation

The study included appropriate control groups and demonstrated no significant effects in these controls. The claim accurately reports the lack of effect in control conditions.

Evidence from Studies

Supporting (1)

Unknown Title

Cross-Sectional Study

In Vitro

Contradicting (0)

No contradicting evidence found

Source Study

Unknown Title

DOI: 10.1155/2015/490681

Similar Assertions

When using a control that doesn't block ER-α, there was no change in cancer cell growth, invasion, or death compared to normal cells.

98%

Using a special virus to deliver a genetic tool that blocks ER-α gene activity successfully lowered ER-α levels in liver cancer cells within a day or two.

87%

Blocking ER-α in liver cancer cells made them grow much slower in lab tests, with about a third less growth in some tests and half fewer colonies forming in soft agar.

84%

Blocking ER-α in liver cancer cells made them much less able to invade through membranes in lab tests, with about 75-80% fewer cells able to move through the barrier.

83%

Blocking ER-α in liver cancer cells made them much less able to invade through membranes in lab tests, with about 75-80% fewer cells able to move through the barrier.

83%